

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 February 2007 (08.02.2007)

PCT

(10) International Publication Number  
**WO 2007/016372 A3**

(51) International Patent Classification:  
C12N 5/08 (2006.01)

(21) International Application Number:  
PCT/US2006/029483

(22) International Filing Date: 27 July 2006 (27.07.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/703,073 28 July 2005 (28.07.2005) US

(71) Applicant (for all designated States except US): **EDEN BIOTECH LTD.** [BS/BS]; Frederick House, Frederick Street, P.O. Box SS-19392, Nassau, The Bahamas (BS).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GHEN, Mitchell, J.** [US/BZ]; EDEN LABORATORIES, LTD., Consejo Shores, Corozal District, XX (BZ). **ROSHAN, Ramesh** [US/BZ]; EDEN LABORATORIES, LTD., Consejo Shores, Corozal District (BZ). **ROSHAN, Romin** [US/BZ]; EDEN LABORATORIES, LTD., Consejo Shores, Corozal District (BZ).

(74) Agent: **LEWIS, Christopher, R.**; RATNERPRESTIA, P.o. Box 980, Valley Forge, PA 19482 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description

(88) Date of publication of the international search report:  
31 January 2008

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR REGENERATING AN IMMUNE SYSTEM


(57) Abstract: An isolated and purified cell line of hematopoietic stem cells (HSC) that are incapable of expressing the CCR5 receptor on the cell surface ("the CCR5 $\Delta$ 32 cells" are used to regenerate the immune system in a subject in need thereof and especially to treat a subject infected with human immunodeficiency virus (HIV). The method is carried out by transplanting CCR5 $\Delta$ 32 into the recipient subject. Because mature immune cells derived from CCR5 $\Delta$ 32 cells cannot express functional CCR5 receptors, they will be resistant to infection by HIV and other pathogens that use the CCR5 receptor to infect cells. An embodiment of the invention includes administration of a nutritional regimen to the patient that optimizes conditions for CCR5 $\Delta$ 32 cell transplantation. Another embodiment of the invention includes co-transplanting mesenchymal cells along with the HSC in order to enhance the growth and development of the transplanted HSC.

WO 2007/016372 A3

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2006/029483

A. CLASSIFICATION OF SUBJECT MATTER		
Int. Cl. C12N 5/08 (2006.01) US Cl. 435/372		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPIDS, MEDLINE, CAPLUS, BIOSIS (hematopoietic, haematopoietic, progenit?, stem, CCR5, CKR5, chemokine receptor 5, non()function?, regenerat?, renew?, restor?, re-establish?, reconstitut?, treat, therapy, transplant?, graft?, HIV, AIDS)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Bai J. et. al., "Characterization of Anti-CCR5 Ribozyme-Transduced CD34 <sup>+</sup> Hematopoietic Progenitor Cells <i>in Vitro</i> and in a SCID-hu Mouse Model <i>in Vivo</i> ", Molecular Therapy, March 2000, 1(3), pg 244-54 See whole document especially Abstract; Pages 245, 248 and 250	1-3, 6, 7, 12, 16
X	US 2003/0039642 A1 (Rader et. al.) 27 February 2003 See whole document especially Pages 3 and 6; Example 3; Claim 1	1-3, 6, 7, 12, 16
X	WO 2004/013330 A1 (Consejo Superior De Investigaciones Científicas et. al.) 12 February 2004 See whole document especially Abstract	1-3, 6, 7
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
* Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	
"P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 31 May 2007	Date of mailing of the international search report <b>28 NOV 2007</b>	
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-3201	Authorized officer:  Blaine R. Copenheaver Helpdesk: 571-272-4300 PCT OSP: 571-272-7774 	

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2006/029483

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Li M-J. et. al., "Long-Term Inhibition of HIV-1 Infection in Primary Hematopoietic Cells by Lentiviral Vector Delivery of a Triple Combination of Anti-HIV shRNA, Anti-CCR5 Ribozyme, and a Nucleolar-Localizing TAR Decoy", <i>Molecular Therapy: The Journal of the American Society of Gene Therapy</i> , 22 August 2005, 12(5), pg 900-9 See the whole document especially the Abstract	1-3, 6, 7
X	Anderson J. et. al., "CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection", <i>Retrovirology</i> , 18 August 2005, 2(53), pg 1-11 See whole document especially the Abstract	1-3, 6, 7
X	Akkina R. et. al., "siRNAs, Ribozymes and RNA Decoys in Modeling Stem Cell-based Gene Therapy for HIV/AIDS", <i>Anticancer Research</i> , May 2003, 23(3A), pg 1997-2005 See whole document especially the Abstract	1-3, 6, 7
X	Bai J. et. al., "Multivalent Anti-CCR5 Ribozymes for Stem Cell-Based HIV Type 1 Gene Therapy", <i>AIDS Research and Human Retroviruses</i> , 20 March 2001, 17(5), pg 385-399 See the whole document especially the Abstract and Page 392	1-3, 6, 7
X	Banerjea A. et. al., "Lentiviral Transduction of Tar Decoy and CCR5 ribozyme into CD34+ progenitor cells and derivation of HIV-1 resistant T cells and macrophages", <i>AIDS Research and Therapy</i> , 17 December 2004, 1(2), pg 1-11 See whole document especially the Abstract	1-3, 6, 7

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

**PCT/US2006/029483**

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. These particulars are merely given for the purpose of information.

Patent Document Cited in Search Report	Patent Family Member
US 2003039462	
WO 2004013330	AU 2003281858
END OF ANNEX	